Media Contacts

1413 K Street NW, 4th Floor
Washington, D.C. 20005
Telephone: (202) 682-2640
Fax: (202) 682-2648

General Inquiries – nwhn@nwhn.org
Media Inquiries – media@nwhn.org

 

  • Judge orders FDA to allow patients to receive medication abortion pills by mail during COVID emergency
    July 14, 2020
    Judge orders FDA to allow patients to receive medication abortion pills by mail during COVID emergency
    The NWHN applauds the recent decision by District Court Judge Theodore Chuang to allow pregnant people to receive medication abortion care through telehealth, including receiving mifepristone through the mail. This is an important public health measure that will improve access to safe early abortion care during the COVID-19 pandemic. The judge’s order will take effect in a few days and applies nationwide.   The preliminary ...
  • The NWHN’s statement on the Supreme Court’s opinion striking down Louisiana abortion restrictions
    June 29, 2020
    The NWHN’s statement on the Supreme Court’s opinion striking down Louisiana abortion restrictions
    Contact: Evita Almassi, ealmassi@nwhn.org Washington D.C. —  Today the U.S. Supreme Court once again upheld the constitutional right of pregnant people to access abortion care without undue burden. But even as we celebrate this important and hard-fought victory, we know we can’t depend on the courts to save us.  The Louisiana law at stake in today’s case ...
  • The NWHN’s statement in support of racial justice and Black Lives Matter 
    June 2, 2020
    The NWHN’s statement in support of racial justice and Black Lives Matter 
    The National Women’s Health Network (the NWHN) supports racial justice and stands in solidarity with the Black Lives Matter movement. We oppose racially targeted police brutality and all forms of discrimination against Black and brown people. We mourn the Black lives lost unnecessarily and prematurely to police violence, including Breonna Taylor, a 26-year old emergency room technician who was shot eight times and killed on March 13th while ...
  • Statement on J&J’s Discontinuation of Its Talc-Based Baby Powder in U.S and Canada 
    May 20, 2020
    Contact: Evita Almassi, ealmassi@nwhn.org  May 20, 2020 Washington D.C. — On May 19, 2020, Johnson and Johnson (J&J) announced that it would stop selling its talc-based Johnson’s Baby Powder in the U.S. and Canada, though existing inventory will continue to be sold through retailers until it runs out. Exposure to talc has been linked to ovarian carcinomas, gynecological tumors, and ...
  • The FDA Must Permit Pregnant People to Get the Abortion Pill Where They Have the Abortion — at Home!
    April 6, 2020
    Contact: Evita Almassi, ealmassi@nwhn.org  Washington DC — Today, the National Women’s Health Network led a diverse coalition of 80 organizations in urging the U.S. Food and Drug Administration to lift medically unnecessary restrictions on mifepristone, the first of two FDA-approved medications used in tandem to induce an abortion. Throughout the United States, patients are turning to telehealth appointments and online pharmacies for routine medical ...
  • The NWHN’s statement on the nomination of Dr. Stephen Hahn to FDA Commissioner
    November 1, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C.- Today, the Trump Administration announced the nomination of Dr. Stephen Hahn to become the next US Food and Drug Administration Commissioner. The National Women’s Health Network calls on Dr. Hahn to publicly commit ...
  • The NWHN statement on the Title X Gag Rule taking effect
    June 24, 2019
    Last year, the Trump-Pence administration rushed through a proposed rule to gut Title X, the country’s family planning program to help low-income individuals access affordable birth control and reproductive health care. Today, a federal appeals court overturned three lower courts and allowed the Title X gag rule to go into effect. This is a devastating ...
  • The NWHN’s Statement on the FDA’s approval of Vyleesi
    June 21, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: 425-749-1886 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. Washington D.C. — The National Women’s Health Network (the NWHN) is disappointed in the United States Food and Drug Administration’s (FDA) decision to approve the drug bremelanotide (brand name: Vyleesi) and urges women to ...
  • Women’s health groups to Congress: We need strong cosmetics standards
    June 20, 2019
    For Immediate Release Contact: Evita Almassi, ealmassi@nwhn.org Washington, D.C. –  Led by the National Women’s Health Network, 42 national, state, and local organizations united by their shared interest in lifting up the voices of women sent a letter today to the House Energy and Commerce Committee applauding the committee for working on a bipartisan discussion draft  to ...
  • The NWHN’s statement on the results of the Evidence for Contraceptive Options and HIV trial (ECHO)
    June 14, 2019
    Contact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-6240 The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network. The National Women’s Health Network (The NWHN) is pleased that the results of the ECHO trial provide reassuring evidence that Depo Provera does NOT significantly increase the risk of HIV infection when compared to ...